These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33854239)

  • 1. The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D.
    Chaikovsky AC; Li C; Jeng EE; Loebell S; Lee MC; Murray CW; Cheng R; Demeter J; Swaney DL; Chen SH; Newton BW; Johnson JR; Drainas AP; Shue YT; Seoane JA; Srinivasan P; He A; Yoshida A; Hipkins SQ; McCrea E; Poltorack CD; Krogan NJ; Diehl JA; Kong C; Jackson PK; Curtis C; Petrov DA; Bassik MC; Winslow MM; Sage J
    Nature; 2021 Apr; 592(7856):794-798. PubMed ID: 33854239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRL4
    Simoneschi D; Rona G; Zhou N; Jeong YT; Jiang S; Milletti G; Arbini AA; O'Sullivan A; Wang AA; Nithikasem S; Keegan S; Siu Y; Cianfanelli V; Maiani E; Nazio F; Cecconi F; Boccalatte F; Fenyö D; Jones DR; Busino L; Pagano M
    Nature; 2021 Apr; 592(7856):789-793. PubMed ID: 33854235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.
    Maiani E; Milletti G; Nazio F; Holdgaard SG; Bartkova J; Rizza S; Cianfanelli V; Lorente M; Simoneschi D; Di Marco M; D'Acunzo P; Di Leo L; Rasmussen R; Montagna C; Raciti M; De Stefanis C; Gabicagogeascoa E; Rona G; Salvador N; Pupo E; Merchut-Maya JM; Daniel CJ; Carinci M; Cesarini V; O'sullivan A; Jeong YT; Bordi M; Russo F; Campello S; Gallo A; Filomeni G; Lanzetti L; Sears RC; Hamerlik P; Bartolazzi A; Hynds RE; Pearce DR; Swanton C; Pagano M; Velasco G; Papaleo E; De Zio D; Maya-Mendoza A; Locatelli F; Bartek J; Cecconi F
    Nature; 2021 Apr; 592(7856):799-803. PubMed ID: 33854232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis.
    Rezaeian AH; Inuzuka H; Wei W
    Adv Protein Chem Struct Biol; 2023; 135():179-201. PubMed ID: 37061331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
    Zhang J; Bu X; Wang H; Zhu Y; Geng Y; Nihira NT; Tan Y; Ci Y; Wu F; Dai X; Guo J; Huang YH; Fan C; Ren S; Sun Y; Freeman GJ; Sicinski P; Wei W
    Nature; 2018 Jan; 553(7686):91-95. PubMed ID: 29160310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.
    Pack LR; Daigh LH; Chung M; Meyer T
    Nat Commun; 2021 Jun; 12(1):3356. PubMed ID: 34099663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer.
    Wen Y; Sun X; Zeng L; Liang S; Li D; Chen X; Zeng F; Zhang C; Wang Q; Zhong Q; Deng L; Guo L
    Adv Sci (Weinh); 2024 Oct; 11(38):e2400666. PubMed ID: 39136283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long-Lost Ligase: CRL4
    Chaikovsky AC; Sage J; Pagano M; Simoneschi D
    DNA Cell Biol; 2021 Dec; 40(12):1457-1461. PubMed ID: 34495753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
    Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
    Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pro-autophagic protein AMBRA1 coordinates cell cycle progression by regulating CCND (cyclin D) stability.
    Maiani E; Milletti G; Cecconi F
    Autophagy; 2021 Dec; 17(12):4506-4508. PubMed ID: 34657573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1.
    Jiang Z; Zhang A; Wei W; Li S
    Sci Rep; 2023 May; 13(1):8389. PubMed ID: 37225761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Biological Evaluation of Novel
    Song X; Gan Q; Zhang X; Zhang J
    Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1.
    Romero-Pozuelo J; Figlia G; Kaya O; Martin-Villalba A; Teleman AA
    Cell Rep; 2020 Apr; 31(2):107504. PubMed ID: 32294430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System.
    Hallett ST; Pastok MW; Morgan RML; Wittner A; Blundell KLIM; Felletar I; Wedge SR; Prodromou C; Noble MEM; Pearl LH; Endicott JA
    Cell Rep; 2017 Oct; 21(5):1386-1398. PubMed ID: 29091774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
    Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
    Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMBRA1 attenuates the proliferation of uveal melanoma cells.
    Zhao B; Yang Y; Cun B; Chen P
    Open Med (Wars); 2022; 17(1):1-14. PubMed ID: 34901460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.
    Oh SJ; Cho H; Kim S; Noh KH; Song KH; Lee HJ; Woo SR; Kim S; Choi CH; Chung JY; Hewitt SM; Kim JH; Baek S; Lee KM; Yee C; Park HC; Kim TW
    Cancer Res; 2018 May; 78(10):2638-2653. PubMed ID: 29437706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.